IFNAR1 and systemic lupus erythematosus: Anifrolumab, an IFNAR1 monoclonal antibody that recently received FDA approval to treat SLE, is another potential drug to be used against the cytosolic DNA sensing pathway in neurodegenerative diseases since symptoms of SLE include significant neurological dysfunction (Morand et al, 2020).